VEGA DAILY

Vitamins to VEGA!

6th. September. 2024

VITAMIN

01

Huaheng Bio announced on the evening of September 4 that the company plans to adjust its 2022 A-share issuance plan to specific objects, and adjust the total fundraising amount from "no more than 1.689 billion yuan" to "no more than 700 million yuan", and the purpose of fundraising will be adjusted from "annual production of 50,000 tons of bio-based succinic acid and bio-based product raw materials production base construction project, annual production of 50,000 tons of bio-based malic acid production construction project, and supplement of working capital" to "annual production of 50,000 tons of bio-based succinic acid and bio-based product raw materials production base construction project, annual production of 50,000 tons of bio-based malic acid production construction project".

AMINO ACID

02

Tryptophan: The current market quotation is stable, terminal demand is weak, users are not active in replenishing stocks, and the actual number of orders signed in the trade market is relatively small. It is expected that the price of tryptophan may weaken slightly in the short term, and attention should be paid to the factory's delivery progress.

API

03

The current market price of colistin sulfate is stable, the delivery time of some factories is tight, and customers are relatively receptive to prices. Factory prices have remained firm recently, and stable operation is expected in the future.

FOOD ADDITIVE

04

Recently, the Natural Products Association (NPA) filed a lawsuit against the U.S. Food and Drug Administration (FDA), asking the FDA to stop illegally retroactively applying the Federal Food, Drug, and Cosmetic Act to nicotinamide mononucleotide (NMN). NMN is a form of vitamin B3. As a precursor to NAD+, it has functions such as supporting energy metabolism, DNA repair, and liver detoxification. It has also been proven to be a safe and effective direct NAD+ precursor. NMN was recognized by the FDA as a legal dietary supplement ingredient in May 2022. However, in October of the same year, the FDA pointed out in its reply to the new dietary ingredient (NDI) notification submitted by Inner Mongolia Jindawei Pharmaceutical Co., Ltd. that NMN violated the definition of dietary supplements in the Federal Food, Drug, and Cosmetic Act, did not fall within the definition of dietary supplements, and could not be sold as a dietary supplement. As the oldest and most powerful natural product industry trade association in the industry, NPA successfully won the lawsuit in 2022, allowing NAC to continue to be sold as a dietary supplement. This lawsuit will also help NMN restore its dietary supplement status in the United States.

Reported by Shea & Livia & Lexie&Oliva&Hannah

ONE STOP SOLUTION SUPPLIER







